Fisher Asset Management LLC reduced its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 10.1% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 12,306 shares of the biopharmaceutical company’s stock after selling 1,376 shares during the period. Fisher Asset Management LLC’s holdings in Gilead Sciences were worth $997,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Rathbones Group PLC purchased a new stake in shares of Gilead Sciences in the third quarter valued at about $302,000. LPL Financial LLC boosted its holdings in shares of Gilead Sciences by 5.9% in the third quarter. LPL Financial LLC now owns 855,585 shares of the biopharmaceutical company’s stock valued at $64,118,000 after acquiring an additional 47,547 shares in the last quarter. Mariner LLC boosted its holdings in shares of Gilead Sciences by 0.7% in the third quarter. Mariner LLC now owns 171,829 shares of the biopharmaceutical company’s stock valued at $12,877,000 after acquiring an additional 1,191 shares in the last quarter. Cary Street Partners Investment Advisory LLC boosted its holdings in shares of Gilead Sciences by 75.3% in the third quarter. Cary Street Partners Investment Advisory LLC now owns 4,289 shares of the biopharmaceutical company’s stock valued at $321,000 after acquiring an additional 1,842 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its holdings in shares of Gilead Sciences by 70.3% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 47,084 shares of the biopharmaceutical company’s stock valued at $3,528,000 after acquiring an additional 19,436 shares in the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.
Insider Activity at Gilead Sciences
In related news, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $72.96, for a total value of $145,920.00. Following the completion of the sale, the insider now directly owns 96,304 shares in the company, valued at $7,026,339.84. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 0.16% of the stock is owned by insiders.
Wall Street Analysts Forecast Growth
Check Out Our Latest Stock Report on GILD
Gilead Sciences Stock Performance
NASDAQ:GILD opened at $70.67 on Friday. The firm has a 50 day simple moving average of $65.74 and a 200-day simple moving average of $72.94. The company has a debt-to-equity ratio of 1.31, a current ratio of 1.08 and a quick ratio of 0.94. The firm has a market cap of $88.04 billion, a PE ratio of 196.31, a P/E/G ratio of 1.38 and a beta of 0.20. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $87.86.
Gilead Sciences (NASDAQ:GILD – Get Free Report) last posted its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.49) by $0.17. The business had revenue of $6.69 billion during the quarter, compared to analyst estimates of $6.36 billion. Gilead Sciences had a net margin of 1.76% and a return on equity of 24.34%. The company’s revenue was up 5.3% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.37 earnings per share. On average, equities analysts expect that Gilead Sciences, Inc. will post 3.75 EPS for the current year.
Gilead Sciences Announces Dividend
The business also recently announced a quarterly dividend, which will be paid on Thursday, June 27th. Investors of record on Friday, June 14th will be issued a $0.77 dividend. The ex-dividend date of this dividend is Friday, June 14th. This represents a $3.08 dividend on an annualized basis and a yield of 4.36%. Gilead Sciences’s payout ratio is 855.56%.
Gilead Sciences Profile
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
See Also
- Five stocks we like better than Gilead Sciences
- What Are Dividend Achievers? An Introduction
- McDonald’s Stock: Balancing Value and Innovation
- Comparing and Trading High PE Ratio Stocks
- MarketBeat Week in Review – 6/17 – 6/21
- The 3 Best Blue-Chip Stocks to Buy Now
- Sarepta Therapeutics Stock Soars on FDA Approval
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD – Free Report).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.